1 / 61

The Use Of Adjuvants In Pain Management

The Use Of Adjuvants In Pain Management. Stewart W. Stein, M.D. Medical Director, Good Shepherd Hospice. Objectives. Understand basic principles of pain transmission Understand the role of adjuvants in the management of pain

Download Presentation

The Use Of Adjuvants In Pain Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Use Of Adjuvants In Pain Management Stewart W. Stein, M.D. Medical Director, Good Shepherd Hospice

  2. Objectives • Understand basic principles of pain transmission • Understand the role of adjuvants in the management of pain • Understand advantages and disadvantages of various agents in the management of chronic pain • Understand the use of other modalities in pain management.

  3. Ascending Pathways • A-delta fibers are myelinated (insulated with a myelin sheath). The pain is fast and well localized, like the initial prick or stinging sensation following an injury. • C fibers are nonmyelinated and smaller than A-delta fibers. They transmit pain much slower. The pain is more lasting, generalized and described as a dull ache.

  4. Ascending Pathways • After afferent A-delta (myelinated and fast) and C-fibers (unmyelinated and slow) synapse with the interneurons. • These cross over to the contralateral side and ascend primarily via the spinothalamic tracts to the thalmus and cortex.

  5. Ascending Pathways

  6. Pathophysiology • Nociceptor activation / Types of receptors: • Mechanical • Thermal • Chemical • Respond to stimuli that approach or exceed harmful intensity by undergoing conformational, electrical and biochemical changes

  7. WHO Pain Ladder

  8. Adjuvant Analgesics

  9. Adjuvant Analgesics • “Non-opioids with analgesic efficacy” • Primarily used to treat neuropathic pain syndromes although also effective in management of nociceptive pain when used as adjuvants to other medications

  10. Adjuvant AnalgesicsStep 1 Agents on the WHO ladder • Non-steroidal anti-inflammatories (NSAIDS) • Antidepressants (TCA’s) • Anticonvulsants / Antiepileptics (AED’s) • Cortisteroids • Bisphosphonates • Anesthetics • N-Methyl D-aspartate antagonists (NMDA)

  11. Acetaminophen / Paracetamol • Mechanism of action unclear but may inhibit cyclooxygenase in the CNS • Acetaminophen can cause liver damage if dose exceeds 4 grams a day • Risk of hepatic injury is increased in patients having pre-existing liver damage (alcoholism, hepatitis) • Acetaminophen has also been shown to cause renal damage.

  12. NSAIDS • Mechanism of action is the inhibition of cyclooxygenase to decrease prostaglandin synthesis • May have central action at the spinal cord level • They do have a ceiling effect • Tolerance and physical dependence is NOT seen! • Can be associated with end-organ toxicity

  13. Neuropathic Pain Syndromes • Trigeminal neuralgia • Post-herpetic neuralgia • Diabetic neuropathy • Chemotherapy-induced neuropathy • Plexopathies • Phantom limb pain • Complex regional pain syndrome • Central post-stroke (damage to thalamus, cortical or subcortical structures) • Syringomyelia • Sympathetically maintained pain syndrome (RSD)

  14. Adjuvant Analgesics • Tricyclic Anti-depressants • Inhibit reuptake of norepinephrine and serotonin in nerve endings in the spinal cord and in the brain • NMDA antagonism

  15. Antidepressants • Tricyclic Antidepressants • Tertiary amines: • amitriptyline • doxepin • imipramine • clomipramine • Secondary amines: • desipramine • nortriptyline

  16. Antidepressants • Serotoninergic agents • Fluoxetine • Paroxetine • Sertraline • Citalopram • Escitalopram

  17. Antidepressants • SNRI’s (serotonin / norepinephrine reuptake inhibitors) • Venlafaxine • Desvenlafaxine • Duloxetine

  18. Antidepressants • Used for: • Analgesia • Depression • Insomnia • (even pruritis)

  19. Antidepressants: • Mechanism of action is inhibition of reuptake of neurotransmitters (serotonin, norepinephrine and dopamine) • Only tricyclic antidepressants have analgesic properties independent of their antidepressant activity

  20. Antidepressants:Side Effects • Nausea • Sedation • Confusion • Xerostomia • Tachycardia • Drug interactions • (Anticholinergic )

  21. Side Effects of TCA’s ?MI • Long term use of TCA’s is associated with a 2.2 relative risk of myocardial infarction and a 1.7fold increase in mortality vs. placebo or SSRI’s. (screen elderly with EKG?) • American Journal of Medicine (2000) Jan;108(1):2-8 • European Heart Journal (2004) 25 (1): 3-9

  22. AED’s (Antiepileptic Drugs)

  23. Mechanism of action of AED’s: • Slow recovery of voltage gated Na channels from depolarization (carbamazepine, phenytoin) • Indirect or direct enhancement of inhibitory Gama-aminobutyric acid neurotransmission (Valproic acid, Tiagabine) • Inhibition of excitatory glutamatergic neurotransmission (lamotrigine)

  24. Mechanism of action of AED’s • Block voltage dependent Ca++ channel (Gabapentin and Pregabalin) • Carbonic anhydrase inhibition (Topiramate, Zonisamide)

  25. Mechanism of action of AED’s:

  26. New AED’s (Anti-Epileptic Drugs) • Gabapentin • Topiramate • Levitiracetam • Tiagabine • Oxcarbazepine • Lamotrigine • Felbamate • Pregabalin

  27. Use of AED’s: • Start with a low evening dose • Increase GRADUALLY over 4-6 weeks depending on response. (Typically effective at higher doses)

  28. New AED’sSide Effects • Drowsiness • Unsteadiness • Aplastic anemia (CB) • Dizziness • Confusion • Rash (VPA) • Ataxia • Nausea and vomiting

  29. Gabapentin • Established efficacy in treatment of post herpetic neuralgia • Most common mistake is failure to titrate to effective doses (900mg ineffective in managing PDN in one series)

  30. Gabapentin • Titration Schedule: • Day 1: 300mg po at HS • Day 2: 300mg po bid • Day 3: 300mg po tid • Titrate 100-300mg per day over next 2 weeks to target dose of 1800mg. Continue titration over 2 more weeks to 3600mg if indicated for effect. Higher doses have also been successfully used.

  31. Pregabalin • Advantages include predictable absorption across the GI tract. Not metabolized or protein-bound. Minimal drug-drug interactions. • Multiple studies demonstrate effective pain relief and decreased sleep interference in PHN and PDN

  32. Pregabalin • Dosing schedule • Days 1-3: 50mg po tid • Days 4-7: 100mg po tid • Thereafter 200mg po tid. • Taper dose over 7 days to discontinue

  33. Lamotrigine • Demonstrated efficacy in trigeminal neuralgia. • Utility in vascular HA’s and PDN suggested by open label studies

  34. Lamotrigine • Dosing: • Start at 25-50mg po daily • Increase by 50mg per day per week until effective or an arbitrary maximum is reached (usually around 900mg daily in 2-3 divided doses)

  35. Topiramate • Studies demonstrate utility in management of cluster headache and diabetic neuropathy • Effective dose range is 200-400mg daily in divided (2) doses • Associated with weight loss • Side effects may include abnormal thinking, delusional and psychotic thinking, kidney stones.

  36. Carbamazepine • Used in trigeminal neuralgia since the 1960’s! • Starting dose is 200mg po bid. Effective dose is usually 400-1000mg per day. • Induces P450 system so potential for drug-drug interactions. • Aplastic anemia occurs in 1:200,000. More commonly, a reversible leukopenia or thrombocytopenia may occur.

  37. Oxcarbezapine • An analog of carbamazepine that retains many therapeutic properties of the drug while avoiding toxicities. (No bone marrow suppression or induction of P450 system) • Start with 300mg at HS. Increase weekly by 300-600mg until effective up to a maximum of 1200-2400mg per day.

  38. Phenytoin • Mixed results in trials (1970’s) for PDN. • Usual dose 200-400mg po daily • Side effects include nausea, diplopia, dizziness, confusion, gingival hyperplasia and rarely Stevens-Johnson syndrome. • Induces P450 cytochrome system

  39. Valproic acid • Demonstrated efficacy in migraine HA’s. • Side effects include nausea, vomiting, sedation, rash, ataxia and appetite stimulation • 40% develop increased transaminases. • 1:50,000 will develop HEPATIC FAILURE

  40. Also part of the equation …. • NNT: The number of patients that need to be treated with a particular drug in order for one patient to experience a 50% reduction in pain • NNH: The number of patients that need to be treated with a particular drug in order for one patient to drop out due to adverse effects

  41. TCA (amitriptyline) • NNT = 2-3 • NNH = 14.7

  42. AED (gabapentin) • NNT = 5.1 (Includes all doses, high and low) • NNH = 26.1

  43. Opioids • Morphine NNT = 2.5 • Oxycodone NNT = 2.6 • Tramadol NNT = 3.9 • NNH for tramadol = 9.0 • NNH morphine and oxycodone = not significant

  44. Bisphosphonates • Pamidronate and Zolendronic acid • Localize to bone and inhibit osteoclastic activity • Widely studied in treatment of metastatic bone pain • Risk of osteonecrosis of the mandible.

  45. Corticosteroids • Inhibit arachodonic acid (prostaglandin synthesis) resulting in anti-infalmmatory action • Also a membrane stabilizer (blocking c-fiber transmission)

  46. NMDA Receptors • Located mostly in the dorsal horn of the spinal cord • Activated by chronic, painful stimulus leading to allodynia, hyperalgesia, and neuropathic pain. • Also responsible for opioid tolerance.

  47. Therefore: • Blocking NMDA results not only in improved pain control but also reverses opioid tolerance to varying degrees.

  48. NMDA receptor antagonists: • Methadone • Ketamine • Dextromethorphan

  49. Ketamine • Useful in refractory neuropathic pain states • Useful to “reset” opioid sensitivity in an opioid-tolerant patient • Also very useful for procedures such as painful wound care

  50. Neuropathic pain:How do we proceed? • If we were to look only at pain relief, the order would be: • TCA • opioids • tramadol • gabapentin / pregabalin (recall NNT)

More Related